TY - JOUR
T1 - CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma
T2 - towards a rational approach
AU - Dreger, Peter
AU - Corradini, Paolo
AU - Gribben, John G.
AU - Glass, Bertram
AU - Jerkeman, Mats
AU - Kersten, Marie Jose
AU - Morschhauser, Franck
AU - Mussetti, Alberto
AU - Viardot, Andreas
AU - European Society for Blood and Marrow Transplantation and the European Hematology Association Lymphoma Group
AU - Zinzani, Pier Luigi
AU - Sureda, Anna
PY - 2023/12/1
Y1 - 2023/12/1
N2 - The approval of CD19-directed chimeric antigen receptor (CAR) T-cell therapies for the second-line treatment of high-risk large B-cell lymphoma (LBCL) has greatly affected salvage algorithms for this condition, and such therapies could have the potential to improve the course of relapsed or refractory LBCL. In this Review, we provide guidance for a rational management approach to the use of commercial CD19-directed CAR T cells in the second-line treatment of LBCL, addressing crucial questions regarding eligible histologies; age, comorbidity, and tumour biology restrictions; the handling of very aggressive tumour behaviour; and holding and bridging therapies. The guidance was developed in a structured manner and, for each question, consists of a description of the clinical issue, a summary of the evidence, the rationale for a practical management approach, and recommendations. These recommendations could help to decide on the optimal management of patients with relapsed or refractory LBCL who are considered for second-line CAR T-cell treatment.
AB - The approval of CD19-directed chimeric antigen receptor (CAR) T-cell therapies for the second-line treatment of high-risk large B-cell lymphoma (LBCL) has greatly affected salvage algorithms for this condition, and such therapies could have the potential to improve the course of relapsed or refractory LBCL. In this Review, we provide guidance for a rational management approach to the use of commercial CD19-directed CAR T cells in the second-line treatment of LBCL, addressing crucial questions regarding eligible histologies; age, comorbidity, and tumour biology restrictions; the handling of very aggressive tumour behaviour; and holding and bridging therapies. The guidance was developed in a structured manner and, for each question, consists of a description of the clinical issue, a summary of the evidence, the rationale for a practical management approach, and recommendations. These recommendations could help to decide on the optimal management of patients with relapsed or refractory LBCL who are considered for second-line CAR T-cell treatment.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85178203452&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/38030311
U2 - 10.1016/S2352-3026(23)00307-1
DO - 10.1016/S2352-3026(23)00307-1
M3 - Review article
C2 - 38030311
SN - 2352-3026
VL - 10
SP - e1006-e1015
JO - The Lancet Haematology
JF - The Lancet Haematology
IS - 12
ER -